HLA-B∗58:01 carrier status of Hmong in Minnesota: First in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol

Kerui Peng, Jonathan Bjork, Ya Feng Wen, Youssef M. Roman, Kathleen Culhane-Pera, May Xia Lo, Elie Gertner, Robert J. Straka

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Allopurinol, a common medication to treat gout, is associated with severe cutaneous adverse reactions, and the occurrence is highly predicted by an individual's HLA-B∗58:01 carrier status. Guidelines endorse preemptive testing in select Asian populations before initiating allopurinol. The Hmong, an Asian subpopulation originally from China who now live dispersed around the world, have a 2.5-fold higher risk of gout when compared to non-Hmong in Minnesota. Given the concern for severe cutaneous adverse reactions when prescribing allopurinol, we quantified the carrier status of HLA-B∗58:01 in Hmong from two independent cohorts in Minnesota. Using a community-based participatory research approach, HLA-B∗58:01 carrier status was determined in 49 US-born Hmong without a history of gout or allopurinol use. Further, 47 Hmong patients undergoing clinical evaluation to receive gout pharmacotherapy were also tested. The frequency of HLA-B∗58:01 positive carrier status in these two cohorts were compared to published data from a Han Chinese (n = 2910) and a Korean cohort (n = 485) using a Fisher's exact test with a Bonferroni-corrected P-value <0.025 for significance. With one uninterpretable result, we identified two out of 95 people (2.1%) who carried HLA-B∗58:01. This 2.1% incidence in these Hmong adults is notably lower than Han Chinese (19.6%, P < 0.0001) and Korean (12.2%, P = 0.0016) populations. Though commonly understood to be of Chinese descent, the lower prevalence within the Hmong underscores the risk of generalizing genotypic findings from Chinese to Asian subpopulations. We suggest no change to the current guidelines recommending which populations should be tested for HLA-B∗58:01 before allopurinol use until further validation.

Original languageEnglish (US)
Pages (from-to)21-25
Number of pages5
JournalPharmacogenetics and genomics
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2020

Bibliographical note

Publisher Copyright:
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

Keywords

  • 58:01'
  • HLA-B
  • allopurinol
  • gout
  • pharmacogenetics
  • severe cutaneous adverse reactions

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'HLA-B∗58:01 carrier status of Hmong in Minnesota: First in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol'. Together they form a unique fingerprint.

Cite this